null

null

null

null

null

null

null

null

null

1.48x Total Debt / Equity (Elevated leverage)

Low sensitivity; Eton carries minimal long-term debt (~$10M credit facility), so a 200bps rate rise adds roughly $200K annual interest expense, immaterial to operations.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) Indian API manufacturers (major generics supply hub); 2) Chinese pharmaceutical raw material exporters — both subject to trade/tariff disruption.

Eton derives ~95%+ revenue from U.S. market; international revenue is negligible, making sovereign currency devaluation risk effectively near-zero currently.

Predominantly U.S.-only commercial footprint; no material international revenue exposure; currency devaluation risk in foreign markets is not applicable at current stage.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Yes — Eton relies on single-source CDMOs for niche pediatric formulations; loss of key CDMO (e.g., Sintetica or equivalent) would materially disrupt product supply with 12–18 month substitution lag.

Specialty pharmaceutical product company; cloud infrastructure termination would disrupt back-office/CRM but not core drug manufacturing or distribution — operational impact moderate, not existential.

Secondary model: royalty/licensing on partnered compounds; cloud termination irrelevant to royalty collection mechanisms which are contract-based.

Minimal API coupling risk; Eton uses standard ERP/CRM software without deep proprietary API integrations; switching costs are low-to-moderate.

Low Howey Test risk; revenue model is pharmaceutical product sales and royalties — clearly a commercial goods/services model, not an investment contract.

Very High

Low GDPR exposure given U.S.-only commercial operations; CCPA exposure modest as patient data is handled by healthcare providers, not directly by Eton.

Low antitrust risk; Eton competes in niche pediatric/rare disease segments with small market share; no dominant market position warranting regulatory scrutiny.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~80–90% transactional (product sales to wholesalers/distributors); ~10–20% recurring via royalties/milestones; limited multi-year contracted recurring revenue.

Primary vector: wholesale pharmaceutical product sales (WAC-based); secondary: licensing royalties on out-licensed compounds to hospital/specialty pharmacy channel.

WAC-based pricing with GPO/PBM rebates; niche pediatric formulations face limited generic competition providing modest pricing durability, but payer pushback is a structural ceiling.

Moderate (6/10); orphan/pediatric designations provide short-term exclusivity pricing leverage, but small market size limits absolute pricing power versus large specialty pharma.

53.5% Gross Margin (Strong (40-60%))

No free-rider problem; pharmaceutical products require prescriptions and purchase — no digital free-tier leakage; churn risk is physician adoption/formulary removal.

Sublinear growth model; Eton outsources manufacturing to CDMOs, enabling revenue scaling without proportional headcount increase; primarily a commercial/regulatory organization.

Low marginal cost per incremental unit given CDMO manufacturing model; primary growth costs are sales force expansion and regulatory filings, not fixed plant investment.

Not applicable; Eton operates no franchise network.

At 10x scale, physician detailing costs remain roughly linear but CDMO volume discounts improve gross margins; key bottleneck is formulary access and hospital contract negotiation capacity.

No meaningful network effects; pharmaceutical product adoption is driven by clinical evidence and physician preference, not user-base size.

-4.9% Return on Assets (Negative equity)

Tier 2 — moderately recession-resistant; pediatric/rare disease medications are medically necessary, but hospital budget cuts and formulary restrictions can slow adoption.

Hospitals and specialty pharmacies (institutional channel); concentration risk exists as top 3 wholesale distributors (McKesson, AmerisourceBergen, Cardinal) represent ~90% of product distribution.

Retail pharmacies and compounding pharmacies as secondary channel; physician prescribers in pediatric/neonatal specialties drive demand pull.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

0.4% CapEx / Revenue (Low-CapEx Asset-Light)

0001710340

ETON